granulocytes

[X4 Pharmaceuticals, Inc.] X4 Pharmaceuticals, Inc. announced that it has completed enrollment in the ongoing pivotal Phase II clinical trial of its lead candidate, mavorixafor, in the treatment of patients with genetically confirmed warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a primary immunodeficiency caused by gain-of-function mutations in the CXCR4 gene.

[iScience] Scientists showed that RSV-induced alveolar macrophages, which produced high levels of matrix metalloproteinase-12, exacerbated allergic airway inflammation with increased neutrophil infiltration.

[Science Advances] The authors showed that the efficacy of immune-stimulatory gene therapy was enhanced in isocitrate-dehydrogenase 1 (mIDH1) gliomas, due to the reprogramming of the myeloid cells’ compartment infiltrating the tumor microenvironment.

[Cancer Medicine] SEC61G expression was analyzed using publicly available datasets. The association between SEC61G and disease prognosis was evaluated.

[Nature] Hematopoietic progenitors from fetal liver, fetal bone marrow and cord blood exhibited transcriptional and functional differences that contributed to tissue-specific identity and cellular diversification.

[Molecular Medicine Reports] The authors determined whether Lycopus lucidus Turcz (LLT) could improve 2,4‑dinitrochlorobenzene‑induced dermatitis and to verify the inhibitory effect of LLT on the expression of chemokines and pro‑inflammatory cytokines in the HaCaT immortalized keratinocyte cell line.